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Tardive syndromes (TS) constitute a group of abnormal involuntary
movements and sensory symptoms caused by exposure to dopamine
receptor-blocking agents (DRBAs). The term tardive reflects the
classical thought that these symptoms occur after long-term exposure
to the DRBA, but it is recognized that TS may appear as early as days
after receiving the first few doses of a DRBA.1
Historically, the main source of TS was the use of first-generation
neuroleptics in the treatment of psychosis. Development of the second-
generation ‘‘atypical’’ antipsychotics led to the initial expectation of a
reduction in frequency of TS, but whether prevalence of TS from the
atypical antipsychotics is lower than the classic antipsychotics remains
controversial. This false sense of safety may have contributed to an
increased number of prescriptions for DRBAs in the past 10 years for
off-label use as mood stabilizers, anti-anxiety agents, and treatments
for agitation in dementia, as well as the use of prokinetic drugs such as
metoclopramide.2 TS have not disappeared with the introduction of
atypical antipsychotics.
A distinct feature of the syndrome is the persistence of the abnormal
movements despite discontinuation of the offending drugs, unlike most
of the other drug-induced side effects, which reverse upon disconti-
nuation of the drug. Available long-term studies of the natural course
of TS provide a wide range of remission rates (0–73%), but most report
remission rates below 25%.1,3–8 The main limitation of most of these
studies has been that patients continued treatment with DRBAs
because of their underling psychiatric disease, or as a symptomatic
treatment for their TS. In this context, an accurate analysis of
evolution of TS is difficult. The continued use of DRBAs can suppress
involuntary movements and mask the diagnosis. Fernandez et al.8
showed a high correlation between an unexpectedly high remission
rate of TS (62%) and an increase in parkinsonism in a group of
patients who are using DRBAs in the long term. This suggests that TS
may have been suppressed by DRBAs that produced parkinsonism.
Similarly, Kane et al.9 showed re-emergence of dyskinesia in 34% of
patients after withdrawal of neuroleptic treatment.
In the recent article by Zutshi et al.12, the authors report a
retrospective analysis of 106 patients with TS in which DRBAs were
discontinued. The majority of these patients (94%) were treated for
non-psychotic disorders, and the DRBAs used were mostly gastro-
intestinal drugs (41.7%) and atypical antipsychotics (36.1%). Patients
were followed for approximately 3 years. Unexpectedly, even after
discontinuation of the causing agents, the rate of spontaneous
remission was only 2%, and the overall remission using specific
treatments was 13%. Unfortunately, probably due to the low remission
rates, the study did not identify any significant predictor of remission in
the patients, their diagnoses, or in the DRBA used. This paper is one of
very few reporting remission rates of TS after complete withdrawal of
DRBAs, and probably the only study in which the majority of subjects
took these medications for non-psychotic disorders.
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As the authors acknowledge, limitations of this study are the
retrospective nature, the selection bias inherent in a Movement
Disorders Center with a tendency to see the most refractory patients,
and a substantial proportion (13%) of the patients lost to follow-up
(arguably those with milder dyskinesias). These factors may have led to
an underestimation of the remission rate of TS. Nonetheless, the
remission rate reported by the authors is strikingly similar to low rates
noted by previous studies from decades ago, before the introduction of
atypical antipsychotic drugs.1,4,7
The pathophysiology of TS is not completely understood and there
have been various proposed mechanisms, including upregulation and
sensitization of post-synaptic D2 receptors in striatal neurons,
increased glutamatergic excitotoxicity, oxidative stress, dopamine
terminal loss, and maladaptive plasticity.10,11 Notably, it is not known
how the changes in synaptic transmission produced by a receptor
antagonist can lead to such persistent changes underlying TS.
On a more positive note, the authors report a general tendency for
improvement of TS in most of the patients. Nonetheless, their finding
stresses the need for further larger prospective studies in patients in
whom DRBAs can be withdrawn and for a better understanding of the
pathophysiology of TS, which defies our knowledge of the pharma-
cological effects of neurotransmitter receptor blockers. Importantly,
the authors’ study and previous studies demonstrating low remission
rates of TS call for a judicious clinical practice that emphasizes
prevention as the best treatment modality at this point.
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